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The use of adeno-associated virus (AAV) as a gene therapy vector is limited by the host neutralizing
immune response. The cryo-electron microscopy (EM) structure at 8.5 A˚ resolution is determined for a
complex of AAV-2 with the Fab’ fragment of monoclonal antibody (MAb) A20, the most extensively
characterized AAV MAb. The binding footprint is determined through ﬁtting the cryo-EM reconstruction
with a homology model following sequencing of the variable domain, and provides a structural basis for
integrating diverse prior epitope mappings. The footprint extends from the previously implicated
plateau to the side of the spike, and into the conserved canyon, covering a larger area than anticipated.
Comparison with structures of binding and non-binding serotypes indicates that recognition depends
on a combination of subtle serotype-speciﬁc features. Separation of the neutralizing epitope from the
heparan sulfate cell attachment site encourages attempts to develop immune-resistant vectors that can
still bind to target cells.
& 2012 Elsevier Inc. All rights reserved.Introduction
Gene therapy involves the delivery to cells of DNA designed to
alleviate disease of genetic nature or predisposition, DNA that
commonly encodes a functional replacement for a mutated gene.
AAV has become a leading candidate vector for gene therapy
because it is non-pathogenic, induces little inﬂammatory
response, integrates site-speciﬁcally into chromosome 19, infects
dividing and non-dividing cells, has wide cell tropism, and is
producible in large quantity (Carter et al., 2008). AAV’s main
disadvantages include a limited gene payload of 5 kb (Dong et al.,
1996) and seropositivity of 35%–80% of the U.S. population to
AAV-2 (Calcedo et al., 2009) (vide infra). Current and recent
clinical trials using AAV vectors are targeting hemophilia B,
prostate and melanoma cancers, Canavan disease, Alzheimer’s,ll rights reserved.
canine parvovirus; CTF, con-
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eases, University of Georgia,Parkinson’s, muscular dystrophy, rheumatoid arthritis and HIV
vaccines (Carter, 2005).
AAV is a non-enveloped virus with a single-stranded DNA
genome surrounded by a protein capsid that is composed of 60
protein subunits related by icosahedral symmetry (Xie et al.,
2002). Three capsid proteins; VP-1, VP-2, and VP-3 are present in
a ratio of 1:1:10, and have molecular weights of 87 kD, 73 kD, and
62 kD, differing (only) in N-terminal extensions of 137 residues
(VP-1) and 64 residues (VP-2) relative to VP-3 (Agbandje-
McKenna and Kleinschmidt, 2011). It is not clear whether VP-1
and 2 substitute for VP-3 at speciﬁc locations in the otherwise 60-
fold symmetric capsid.
Immune responses to AAV are mild and non-inﬂammatory,
signiﬁcantly reducing the possibility of complications during
treatment (Bueler, 1999; Chirmule et al., 1999). However, immune
response still presents a signiﬁcant barrier to efﬁcient delivery of
the vector during initial treatment, as neutralizing antibodies have
been found in up to 60% of the population (Blacklow et al., 1968;
Boutin et al., 2010; Calcedo et al., 2009; Chirmule et al., 1999;
Moskalenko et al., 2000). Clinical trials involving experimental
cystic ﬁbrosis and hemophilia treatments required re-administra-
tion of therapies (Flotte and Carter, 1998; Kay et al., 2000). As only
10% of progenitor cells below the lung epithelium are trans-
duced, transgene expression falls over 6 months as surface cells
are turned over (Carter and Flotte, 1996). Exposure to natural AAV
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neutralizing antibodies (Halbert et al., 2000; Moskalenko et al.,
2000; Peden et al., 2004; Xiao et al., 1999). This can decrease the
efﬁciency of transgene expression upon subsequent
administration(s) of vectors of the same serotype (Davidoff et al.,
2005; Manno et al., 2006; Wang et al., 2010, 2011). Cellular
immune response is largely directed against the viral capsid, while
immune response to the transgene product is rare (Brockstedt
et al., 1999; Chirmule et al., 2000; Halbert et al., 1997; Hernandez
et al., 1999; Manning et al., 1998). Therefore, it is widely thought
that the engineering of antigenic variant vectors will have sub-
stantial impact in the development of efﬁcient gene therapy
treatments (Flotte, 2005; Peden et al., 2004; Xiao et al., 1997).
A20 is a monoclonal antibody which neutralizes AAV-2 and
AAV-3B subsequent to primary receptor binding (Wobus et al.,
2000). It does not bind to the other predominant serotypes 1, 4, 5,
6, 8 and 9 (Murphy et al., 2008; Wobus et al., 2000; Wu et al.,
2006; Xie et al., 2011). It is the most widely studied monoclonal
antibody against AAV-2, due in part to its ability to bind only to
fully assembled capsid and not to unassembled capsid proteins
(Moskalenko et al., 2000; Wistuba et al., 1995; Wobus et al., 2000).
It has been suggested that there are at least three neutralizing
immunogenic sites on the capsid of AAV-2 (Lochrie et al., 2006),
therefore it is unlikely that mutations solely within the A20
footprint will yield a capsid that is completely distinct antigeni-
cally. However, two mutations which inhibit A20 neutralization
also confer resistance to polyclonal neutralization, suggesting that
A20 binding might model neutralization at a dominant epitope
(Lochrie et al., 2006). There have been multiple attempts to locate
the A20 epitope using various techniques, including PEPSCAN,
peptide competition, peptide insertions, and both site-directed
and scanning mutagenesis (Girod et al., 1999; Lochrie et al., 2006;
Moskalenko et al., 2000; Shi et al., 2001; Wobus et al., 2000; Wu
et al., 2000). Lochrie et al. (2006) have drawn attention to
inconsistencies between some of the experimental epitope map-
pings, and between some of the proposed immunogenic sites and
the subsequent AAV-2 atomic structure (Xie et al., 2002), noting
that inaccuracies result from known limitations of standard
methods (Van Regenmortel, 1992). There has long been an interest
in resolving these questions through direct visualization of an
AAV-2/A20 complex (Lochrie et al., 2006).
We present here a cryo-EM reconstruction of AAV-2 in com-
plex with A20 monoclonal Fab’ antibody at a resolution of 8.5 A˚.
The antibody-binding footprint of AAV-2 has been determined
from the previously determined crystal structure of AAV-2 by
ﬁtting a homology model of A20 Fab’ into the experimental
density of the complex. To our knowledge, this is the ﬁrst
structure of an AAV-antibody complex. The binding interface is
compared with the corresponding surfaces of closely related
viruses for insights into the characteristics of serotypes that
might determine whether or not a virus is recognized by A20.Fig. 1. Fourier shell correlation. At a conservative threshold of 0.5, the resolution
would be assessed as 8.5 A˚. A threshold of 0.143 yields 6.7 A˚.Results and discussion
Use of Fab’ fragments
EM imaging takes advantage of the 60-fold icosahedral sym-
metry, for which it was important to achieve near saturated
binding of equivalent binding sites on the virus. At the required
stoichiometries, attempts to image the complex of AAV-2 with
intact puriﬁed MAb A20 were foiled by aggregation, either when
virus and antibody were pre-mixed in solution, or when antibody
was added to virus pre-loaded onto EM grids. With papain-
digested Fab fragments, prepared the conventional way, neither
unstained or negatively stained EM revealed fragments bound tothe AAV surface. Even large excesses of Fab failed to compete with
intact Mab in dot-blot assays using biotinylated Mab A20. These
data suggested that the papain-digested fragments were not
stable in a native fold. By contrast, pepsin-digested Fab’ fragments
competed with MAb in dot-blot assays, and could be seen
decorating the surface of AAV-2 in negatively stained EM images.
Electron microscopy reconstruction
The complex of AAV-2 with Fab’ fragments of neutralizing
monoclonal antibody A20 (Wistuba et al., 1995) was visualized
through cryo-EM and reconstructed to a resolution of 8.5 A˚
(FSC0.5) (Fig. 1). 11,898 particles from 1066 images were com-
bined in a 3-D reconstruction. Class averages of the complex
resolved the variable and constant Fab’ domains, with the
presumptive variable domain, bound to the capsid surface, better
deﬁned than the constant domain (Supplementary Fig. 1). The EM
reconstruction clearly shows the distinctive features of AAV,
previously seen in the uncomplexed virus (O’Donnell et al.,
2009; Xie et al., 2002), namely the threefold peaks, the 5-fold
cylinder, 2-fold valley, canyon, and plateau (Fig. 2). All of the
differences in the capsid density between the complex and native
forms could be attributed to differing resolution, i.e., there is no
evidence of large scale antibody-induced conformational change
in the virus.
Homology modeling
A20 is a murine Ig3 antibody whose sequence and 3-D
structure have not previously been reported. Using sequences
determined here for the variable regions of light and heavy chains
(Table 1), Modeller (Eswar et al., 2006) was used to create a
homology model of the antibody’s variable region. The structure
of the complementarity determining regions (CDRs) depends on
loop reﬁnement, sometimes a challenging step, so the homology
model was checked against the database of CDR conformation,
based on 4300 antibody structures (North et al., 2011). CDR
conformers were used if their database frequency, among those
with A20-matching sequence motifs, exceeded 5% (North et al.,
2011). Excluding two conformations of CDR H3 with 5 and 11 Ca
atoms outside the A20 density, respectively, the frequency-
weighted RMS Ca distance between the A20 homology CDRs and
matching database conformers was 0.7 A˚. Five of the 6 CDRs were
in excellent agreement (RMS Ca¼0.4 A˚), with greater uncertainty
in H3 (RMS Ca¼1.5 A˚). In principle, the homology model, built to
ﬁt the cryo-EM density (Eswar et al., 2006), should be superior to
the un-optimized density-independent cluster structures, and the
discrepancy between them provides an upper-limit estimate of
the homology model backbone error.
Fig. 2. Reconstruction of AAV-2 complexed with A20 Fab’ (A) compared to a prior cryo-EM reconstruction of native AAV-2 (B) (O’Donnell et al., 2009). The view is along a
2-fold with additional 2-fold axes horizontal and vertical. The asymmetric unit is outlined in panel B with a pentamer at the 5-fold vertex, triangles at the 3-folds and an
oval at the 2-fold axis. Reconstructions are colored by radius from the center from blue to red. The canyon surrounding each 5-fold and the depressed area near each 2-fold
are blue, the cylinder and plateau are green, and both the 3-fold proximal viral spikes and Fab’ are red. (C) Fit of the homology model into the density of the cryo-EM
reconstruction. Two symmetry-equivalent Fab’ fragments are shown in blue (pale for the light chain, dark for heavy) with CDRs highlighted according to the color key, H1-
3 and L1-3. AAV-2 is shown in green with variable regions VR-I, -III, -VII and -IX, the main CDR contacts, highlighted in color. The view is tangential to the virus surface
with yellow arrows indicating symmetry axes, 2-folds on each side, and looking from a 3-fold (front center) towards a 5-fold (out of view). Density is contoured at 2.5 s.
Fig. S4 shows a stereographic version of panel C, from which the quality of ﬁt can be more readily appreciated.
Table 1
Sequence of the A20 variable regions for both light and heavy chains. The complementarity determining regions (CDR) are annotated for each chain.
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Initial rigid group reﬁnement using RSRef (Chapman, 1995)
relieved strain in the inter-molecular van der Waals energy (by
20%) with little change in the quality of the ﬁt (CC¼0.775).
(Correlation coefﬁcients are calculated for voxels of the map
within 10 A˚ of any Fab’ or virus atom.) Least-squares ﬁtting of a
Butterworth low-pass ﬁlter to the model density lowered the
residual difference with the experimental density by 1%, and
suggested that the effective resolution of modeling was slightly
lower (10.6 A˚) than would be expected of the FSC0.5 (8.5 A˚), noting
that the former reﬂects the limitations of both experiment and
modeling. Splitting the Fab’ into variable and constant domainsled to only a small improvement in correlation (0.778 to 0.781),
but a 40% improvement in intra-protomer van der Waals energy
as strain was released. Occupancy of the FAb’ reﬁned robustly to
1.0, indicating saturated binding. Reﬁnement of isotropic group
atomic displacement parameters (ADP, ‘‘B-factors’’) showed that
the variable domain was indistinguishable from the capsid
protein (/BS¼23.5 A˚2), but the more distal constant domain
had an optimal B of 300 A˚2. These correspond to rms harmonic
displacements of U¼0.3 A˚ and U¼2 A˚ for the variable and
constant domains, respectively. Thus, the variable domain can
be considered tightly bound with displacement parameters
that reﬂect the experimental resolution. By contrast, constant
domain displacements of 2 A˚, and perceptibly more diffuse EM
D.M. McCraw et al. / Virology 431 (2012) 40–49 43density, are consistent with ﬂexibility at the hinge. A ﬁnal
round of positional reﬁnement converged at CC¼0.787 (Fig. 2).
From start to end of this reﬁnement the rms coordinate change
was 0.8 A˚.Fig. 3. Stereographic polar projections of the Fab’ A20 footprint (outlined in black) on
distance from the viral center, from blue (105 A˚) to red (140 A˚). (A) Footprint determined
(B) Footprint determined directly from the 8.5 A˚ density, contoured at a level to corresp
line); (C–F) Projections of the AAV-3B (C), AAV-4 (D), AAV-6 (E), and AAV-8 (F) structuBinding site
With virus-Fab complexes, it is usual to analyze the interface
indirectly, using a model ﬁt to the Fab density, because theto the AAV asymmetric unit, outlined by the triangle (see Fig. 1B). Color indicates
from a homology model ﬁt to the EM density projected onto the surface of AAV-2;
ond to the solvent-excluded volume (thick line) or solvent-accessible surface (thin
res onto which is overlaid the AAV-2 Fab’ footprint from panel A.
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chemical restraints in crystallographic reﬁnement, can support
analysis beyond the nominal experimental resolution (Rossmann,
2000). It does introduce the errors of Fab homology modeling,
which are modest for the backbone (see above) and depend
mostly on uncertainty in choice of side-chain rotamers. It there-
fore limits analysis to amino acid level, which is nevertheless a
potential improvement upon the 8.5 A˚ primary data.
It was cross-checked in two ways (Table S1). A model-indepen-
dent footprint was determined by tracing saddle-point vectors
between the virus and Fab densities, contoured to correspond to
either the solvent excluded or solvent accessible volumes
(Gerstein et al., 2001). Footprints from the solvent-excluded
density and homology model are similar (Fig. 3), sharing 12 of
16 amino acids, and only 2 homology model contacts fall outside
the footprint density contoured to approximate the solvent
accessible surface. The impact of homology modeling errors was
also assessed by comparison with an alternative model (see
above), consisting of spliced loops from Dunbrack’s CDR database
(North et al., 2011) with matching sequence motifs. 80% of the
contact residues were identical. In summary, of 16 footprint
residues implicated by the homology model, 12 are robustly
implicated by all methods, two are doubtful (Ser658 and Thr660)
lying outside the density footprint, and a total of 7 additional
residues on the periphery are suggested as possibilities by one or
more of the alternative approaches. Discussion will be framed
around the core consensus footprint, except as explicitly noted.
Residues implicated in the footprint are listed in Table 2 and
Table S1 and illustrated in Fig. 3. The footprint is comprised of
multiple peptides contributed by three different symmetry-
related subunits, explaining why MAb A20 is speciﬁc for
assembled capsids (Wobus et al., 2000). It encompasses regions
of diverse sequence on the plateau and side of the spike, but also
nearly as many in the more conserved canyon region. The more
exposed parts of the footprint contain residues from 4 of 9
‘‘variable regions’’ (VR) previously noted to have the highest
sequence diversity among AAVs (Agbandje-McKenna and
Chapman, 2006; Govindasamy et al., 2006). Earlier difﬁculties in
linear epitope mapping are explained by the ﬁnding that 6 distinct
segments of polypeptide chain contribute to the footprint; mAb
A20 binds to a conformational epitope deﬁned by protein tertiary
structure, and not a simple linear sequence of amino acids.
It has been reported that human rhinovirus is neutralized by
bivalent antibody attachment in some cases (Hewat and Blaas, 1996;
Rossmann et al., 1985). For bivalent attachment adjacent Fab C-ter-
mini need to be located within 25–29 A˚ of each other (Hewat and
Blaas, 1996; Hewat et al., 1998; Thouvenin et al., 1997). For the A20
homology model, the closest symmetry-related C-terminal ends of
A20 Fab’ are 47 A˚ apart. The resolution and distinctive features of the
reconstruction leave little ambiguity in the orientation of the Fab’,Table 2
Regions of AAV-2 contacted by MAb A20. Residues were identiﬁed that fell within
4 A˚ of the ﬁtted Fab’ homology model. Most of the footprint is validated by
comparison to two independent assessments (Table S1). Parentheses denote
residues on the periphery that were not implicated by all three approaches.
AAV-2 residues Subunit Variable region
Plateau 261SSQS264 B I
Ser384, Gln385 B III
Val708 A IX
Asn717 A
Canyon wall Lys258 B
Canyon Asn253, Asn254 B
658(S)T(T)660 I
Spike (Glu548, Lys556) A VIIwith the C-termini of the heavy chain Fab’ fragments pointing
outwards away from their nearest neighbor. Bivalent attachment of
an intact antibody would require implausible levels of distortion at
the elbow (relative to the observed conﬁguration), and displacements
that would be 10-fold greater than any disorder implied in the
constant domain B-factors. Thus, although symmetry-related anti-
body footprints come within 12 A˚ of each other, the structure is
compatible with only monovalent attachment.
MAb A20 neutralizes at a step subsequent to cellular attach-
ment (Wobus et al., 2000). AAV enters cells endosomally, after
initial attachment to a heparan sulfate proteoglycan (HSPG)
(Summerford and Samulski, 1998), and subsequent binding to
one of several possible protein co-receptors (Agbandje-McKenna
and Kleinschmidt, 2011). The HSPG binding footprint has recently
been mapped by electron microscopy (O’Donnell et al., 2009).
Co-receptor footprints are currently unknown. (A site suggested
by mutations affecting transduction but not heparin-binding
(Lochrie et al., 2006) actually fell within the HSPG footprint
(O’Donnell et al., 2009), so the sensitivity of heparin binding
assays may not support such speciﬁc designations.) Here, we see
that the MAb A20 and heparin binding footprints do not overlap.
This is consistent with the earlier ﬁnding that A20 does not
inhibit cellular attachment (Wobus et al., 2000). It remains to be
seen whether A20’s neutralization results from interference with
co-receptor mediated entry, or conceivably some later step. A20
occludes considerably more of the surface than the footprint
residues making direct contact and thus could affect other
interactions essential to AAV’s life cycle. A20’s variable domain
extends deep into the canyon and is nestled between the 5-fold
cylinder and the 3-fold spikes. Although none of the residues of
the cylinder and only two of the spike make direct contact, the
gap between virus and antibody is narrow enough here to shield
additional residues from interacting with macromolecules that
might be essential to AAV’s life cycle.
Comparison with autonomous parvoviruses
There are not yet other Dependovirus-antibody complexes with
which to compare, but there are several cryo-EM structures from
the autonomous parvoviruses of the sister genus Parvovirus. The
greatest similarities are with antibodies that bind to epitope B of
the closely related pair, canine parvovirus (CPV) and feline
panleukopenia virus (FPV) (Hafenstein et al., 2009; Wikoff et al.,
1994) (Fig. S1). The AAV-2 A20 binding site therefore contrasts
with the binding site of MAb B7 of minute virus of mouse (MVM)
which is directly above the 3-fold axis of symmetry (Kaufmann
et al., 2007). The surface topology of the autonomous viruses at
the B7 site differs from AAV with loops from adjacent subunits
coming together to form more of a single elevated ‘‘massif’’. AAV
has 3 distinct protrusions, between which are valleys that meet at
the 3-fold, so the B7 site is less accessible. However, some
common themes are emerging. None of the complexes, including
AAV-2/A20, are compatible with bivalent attachment, and several
of the binding sites: MVM B7, CPV/FPV B-site and AAV2 A20, are
at interfaces where loops from neighboring subunits come
together to deﬁne the viral structure.
Cryo-EM-deﬁned footprints for six CPV/FPV MAbs overlap at
site ‘‘B’’, comprised mostly of loop 3, a region implicated by
mutagenesis to be antigenic (Hafenstein et al., 2009; Wikoff et al.,
1994). CPV residues 298 to 302 superimpose over the AAV-2 A20
footprint if aligned by icosahedral symmetry. The B site and VR1
of the AAV-2 A20 footprint are located on the plateaus of their
respective viral surfaces. In CPV/FPV, bound antibodies overlap
with the binding site of the transferrin receptor, blocking both
viral attachment and subsequent entry steps (Hafenstein et al.,
2007), but the steps of AAV entry and mechanisms of A20
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similarities appear to result from convergent evolution, because
AAV’s VR1 does not correspond in primary structure with loop
3 of CPV/FPV. VR1 is in the loop between b-strands B and C, which
in CPV/FPV is pushed up from the plateau as part of the 3-fold
massif, and comprises epitope A, to which a distinct set of 3 MAbs
bind (Hafenstein et al., 2009). Paradoxically, epitope B (on the
plateau of CPV and FPV) is formed by residues from the loop
between strands G and H whose equivalents are at the exposed
tip of the 3-fold protrusions in AAV. In the autonomous viruses,
the plateau extends further out from the 3-fold axis, and the
footprints of B-site antibodies all fall within the bounds of
the plateau. With AAV-2, the topography is more varied, and for
the ﬁrst time we see an Fab binding site extend over the edge of
the plateau into a more prominent and less exposed canyon.
Epitope
As the ﬁrst AAV neutralizing monoclonal antibody (Wobus
et al., 2000), MAb A20 has been the subject of repeated epitope
mappings using multiple approaches (vide infra). The AAV-2
crystal structure (Xie et al., 2002) showed that not all regions
implicated by peptide scanning (Moskalenko et al., 2000; Wobus
et al., 2000) could fall within a typical antibody footprint, or,
indeed were near the outer surface of the virus. Thus, structure
has already helped integrate the molecular data, complementing
scanning approaches and their known limitations (Van
Regenmortel, 1992). Visualization of the A20-AAV2 binding inter-
face provides an additional perspective. Exact consistency with
molecular approaches should not be expected, due to ambiguities
in each approach, including the potential for wider conforma-
tional change in escape mutants, and limited precision in struc-
tural studies at 8.5 A˚ resolution (see above). Nevertheless,
integration of a physical epitope from EM visualization with the
functional molecular approaches can provide a more robust
understanding of immunogenicity.
There has been wide variation in surface sites implicated in A20
binding, but the plateau has been implicated more often than other
regions. Single residue substitutions at 64 surface-exposed sites
revealed a cluster that affected A20 binding or neutralization: Q263,
S264, S384, Q385 and V708 (Lochrie et al., 2006). These are all within
the EM footprint, and are joined in close proximity by the sites of
peptide insertions after S261, A266, N244 and S247, the ﬁrst three of
which inhibited A20 binding (Girod et al., 1999; Wu et al., 2000).
Thus, from this molecular data and our structure, a consistent picture
emerges that an important part of the A20 epitope is the plateau
where the VR-I and VR-III loops from one subunit and VR-IX from a
neighbor pack together.
The EM reconstruction shows the A20-AAV2 binding surface
extending into the canyon, a region that was not tested by Lochrie
et al. (2006) or other studies. To the EM footprint are added S261,
S262 and N717 on the edge of the plateau, K258 on the wall, then
N253, N254, T659 and possibly S658 and T660 in the canyon. As in
the complex of human rhinovirus (HRV) 14 with Fab17-1A (Smith
et al., 1996), the CDRs of MAb A20 penetrate a less exposed, more
conserved region of the surface, although in AAV, the region has not
yet been associated with any viral function. Extending the binding
site into the canyon approximately doubles the size of the footprint
implicated by Lochrie’s cluster of plateau mutants.
The core residues of the footprint are implicated both in
model-based calculation of contacts, and in projections of experi-
mental Fab’ density onto AAV-2 that are not dependent on
modeling the Fab’. A few residues on the periphery are less
certain, because their designation is sensitive to the choice of
solvent probe or density contour level. E548 and K556 come
within 4 A˚ of modeled A20 atoms, but are connected by densityonly at lower contours corresponding to the solvent accessible
surface. Mutation of E548 has been seen to yield a small 3-fold
resistance to A20 neutralization (Lochrie et al., 2006) or, like K556
(ibid), to have no impact upon binding (Wu et al., 2000). It seems
likely that the observed proximity of the Fab’ to two residues on
the side of an adjacent AAV-2 spike is incidental and not critical to
the binding interactions. Indeed, the spike residues are apparently
not part of the epitope, because the contact would be with
conserved framework residues towards the side of the immuno-
globulin domain, not CDR loop residues usually associated with
antigen recognition.
Distinctiveness of AAV-2 and AAV-3B
AAV-2 and AAV-3B are the only serotypes which are bound
strongly by A20. A search was made for distinguishing character-
istics of the footprint that are conserved between AAV-2 and AAV-
3B, but distinct for non-bound serotypes. As at 8.5 A˚ resolution,
side chain conformation is not deﬁned for the Fab’, comparison of
atomic interactions was not possible, but high resolution struc-
tures for AAV serotypes supported comparison of viral surface
properties within the footprint region.
In sequence, AAV-3B differs from AAV-2 only at three binding site
residues, all on the edge of the A20 footprint: S658 is replaced by
P659 in the canyon, while E548 and K556 of AAV-2 are replaced by
T549 and N557 in AAV-3B on the side of the spike (Fig. 3). Lochrie
et al. (2006) found only modest impact on A20-binding of even non-
conservative mutations at E548 and K556. The contact at E548/K556
in the AAV-2 complex is superﬁcial, relative to other interactions.
Density bridges only when contoured to enclose the solvent acces-
sible, but not the van der Waals surface (Table S1). Furthermore, the
contact is made by a conserved (non CDR) part of A20, all suggesting
that the contact might be incidental. Thus, the core of the footprint is
conserved between AAV-2 and -3B, and differences are restricted to
peripheral residues that have at most modest impact on binding
(Lochrie et al., 2006).
Most of the differences in the surface topology of other serotypes
lie outside the binding site. Within the canyon, AAV-2, -3B, -4, -6, and
-8 are very similar. There are subtle differences on the plateau, but
these are not obviously correlated to A20 binding. For example, AAV-
6 (non-binding) is more similar to AAV-3B (binding) than is AAV-2
(binding). In the footprint region, there are not systematic differences
in amino acid polarity or electrostatic charge that would clearly
disrupt binding. Local changes are exempliﬁed by a threonine
insertion after S264 and/or a Q263A substitution in AAV-6, -1 and
an AAV-2/-1 chimeric construct (Hauck and Xiao, 2003). These would
not create large steric conﬂicts with A20 (Fig. 3A and C). Analysis of
subtle changes in interactions, that are presumably important,
requires greater precision in A20 side chain structure than available
in an 8.5 A˚ homology-based model.
For future efforts to engineer gene therapy vectors with reduced
susceptibility to immune neutralization, the reported structure is
encouraging. The footprint is larger than previously anticipated,
providing a wider choice of residues to mutate for immune
neutralization escape. Relatively modest changes can affect antibody
binding, and there is no overlap for binding sites of receptor HSPG
and this model antibody, increasing the prospects for engineering
the vector without disrupting cell attachment.Methods
Preparation of AAV-2 and A20 Fab’
AAV-2 was produced as described previously (Xie et al., 2004).
Stocks of hybridoma cells for A20 were generously provided by
D.M. McCraw et al. / Virology 431 (2012) 40–4946Ju¨rgen Kleinschmidt. They were grown by seeding 25106 cells
in 15 mL of 90% RPMI media (Sigma–Aldrich) and 10% FetalClone
1 serum (Hyclone) in a CELLine CL 1000 bioreactor (Integra). The
bioreactor was maintained using 98% RPMI and 2% FetalClone
1 serum. Antibodies were harvested after 1 week. Cells were
pelleted out by centrifugation at 70 g for 5 min and the
supernatant was passed through a 0.45 mm ﬁlter. Secreted anti-
bodies were puriﬁed with a HiTrap protein G afﬁnity column
(GE Healthcare).
The antibody solution was dialyzed into 20 mM sodium
acetate (pH 4.5) and digested with immobilized pepsin (Thermo
Scientiﬁc), as per the manufacturer’s protocol, to yield F(ab2)’. The
F(ab2)’ solution was dialyzed overnight into 20 mM sodium
phosphate (pH 7.2). Undigested IgG and Fc fragments were
removed using a HiTrap protein A afﬁnity column (GE Health-
care). Flow-through fractions containing F(ab2)’ were dialyzed
into 150 mM PBS and 5 mM EDTA (pH 7.2) using a Float-A-Lyzer
G2 (Spectra/Por) with a 50 kD molecular weight cutoff.
The F(ab2)’ solution was reduced with Mercaptoethylamine-
HCl (2-MEA; Thermo Scientiﬁc) according to the manufacturer’s
protocol. The resultant crude Fab’ solution was immediately
puriﬁed by size exclusion chromatography with Superdex 200
(GE Healthcare) using a running buffer of 150 mM sodium
chloride, 50 mM sodium phosphate, and 5 mM EDTA (pH 7.2).
Gel electrophoresis with silver staining was used to assess
purity.
Preparation and cryo-EM of the AAV2-A20 Fab’ complex
AAV-2 in 100 mM HEPES, 50 mM magnesium chloride, and 5%
glycerol (pH 7.2) was incubated with a 4-fold excess of puriﬁed
Fab’ (240 Fab’ fragments per 60-fold symmetric virus) for 30 min
at 25 1C. Small aliquots of this mixture were applied to holey
carbon grids (C-ﬂat). The sample was then ﬂash-frozen by plun-
ging using a Vitrobot (FEI) at 100% humidity and 4 1C, using a 2 s
blot time. 1503 images of the specimen were collected at
37,000 magniﬁcation and 120 keV on a FEI Titan Krios equipped
with a Gatan Ultrascan 4k4k CCD camera using the Leginon
system (Suloway et al., 2005). The ﬁnal pixel size was 2.225 A˚.
Reconstruction of AAV2-A20 Fab’ complex
Appion (Lander et al., 2009) was used for particle picking, CTF
estimation, and stack making. Initial particle selection was per-
formed using the difference of Gaussians method (Voss et al.,
2009) and particles over carbon were manually deselected. CTF
estimation was performed with the ACE (Automated CTF Estima-
tion) software package (Mallick et al., 2005). Images with an ACE
CTF estimation conﬁdence value of less than 0.7 were removed
from the data set after which a 35,543 particle stack was made
with the phases ﬂipped for individual particles according to their
ACE-estimated defocus. EMAN (Tang et al., 2007) was used for
subsequent reﬁnement and reconstruction. Reﬁnement ﬁrst
yielded a reconstruction with a resolution of 9.8 A˚ by the FSC0.5
criterion. Inspection of the class averages from the reﬁnement
suggested conformational heterogeneity in the Fabs. Subclassiﬁ-
cation was employed to test for and, as necessary, remove
heterogeneity. Multivariate statistical analysis was performed
on each class of particle projection following each iteration of
reﬁnement. Correspondence analysis was performed with hier-
archical ascendant classiﬁcation on aligned particles in a given
orientation. This generated 2–6 subclasses for each projection.
Only the subclass correlating best with the projection of the
current model was included in the reconstruction for that itera-
tion. After reﬁnement, this procedure resulted in an 8.5 A˚ resolu-
tion (FSC0.5) ﬁnal reconstruction based on 11,898 particles. Thewhole reﬁnement was repeated using two different starting
models: a prior reconstruction of the native virus (O’Donnell
et al., 2009); and a model created de novo using the EMAN
STARTICOS program. These independent reﬁnements converged
on the same solution.
Scaling
Correction of the relative magniﬁcation proved to be critical.
After data collection, it was discovered that the relevant magni-
ﬁcation calibration parameter had not been set appropriately in
this ﬁrst structure determined using a newly commissioned
microscope. Thus, such a large correction to the relative magni-
ﬁcation (1.075) had not been anticipated. Three approaches
yielded the same value for the relative magniﬁcation. First, a
search was made for the best agreement between the density of
the complex and an earlier reconstruction for the native virus
(O’Donnell et al., 2009), masking out Fab’ density through use of
radial cut-offs of 72 and 120 A˚. Second, a search was made for
the highest correlation between the experimental map of the
complex, and the local density calculated from the AAV-2
(uncomplexed) crystallographic structure (Chapman, 1995; Xie
et al., 2002). Finally, the magniﬁcation was least-squares reﬁned
by optimizing the agreement of the full atomic model of the
complex (see below) and the experimental EM density. Correc-
tion of the magniﬁcation had a dramatic impact on the ﬂatness
of difference maps, and the model-map correlation, improving
from 0.2 to 0.7.
Creating a homology model
Initially, the Fab’ was modeled using an arbitrarily selected
antibody from the protein data bank (PDBid 1A6T), without
reference to the actual sequence of A20. This was sufﬁcient to
uniquely deﬁne the approximate orientation of the Fab’ (Fig. S3),
but a more accurate binding footprint would require a homology
model with CDRs of length and conformation appropriate to the
sequence of MAb A20. RNA was extracted and cloned from snap-
frozen hybridoma cells for PCR ampliﬁcation using degenerate
VH and VL primers and bidirectional cDNA sequencing of the
A20 variable domains (Molecular Cloning Laboratories). Mod-
eller (Eswar et al., 2006) was used to create a homology model of
the antibody’s variable region. 19 structures from the protein
databank with a sequence similarity of 58% or greater were used
as templates. 1000 models were produced by aligning the
templates to the A20 sequence. Of these, the top 100 models
had DOPE scores ranging from 12,337 to 12,149 and were
ﬁtted into the density by Modeller. Of these, the top 10 models
had a correlation coefﬁcient of 0.85–0.86. The model with the
highest combined DOPE score and correlation coefﬁcient was
used as the variable domain in an initial homology model for
A20. To model the constant region, of known IgG Fab crystal
structures, mouse monoclonal antibody 184.1 (PDBid 1OSP
(Li et al., 1997)) was chosen on the basis of the highest sequence
identity.
CDR database models
Alternative models for the variable domain were generated
from the Dunbrack database of CDR loop conformations compiled
from 4300 non-redundant high resolution crystal structures
(North et al., 2011). For CDRs of a given length, conformations
fall into a handful of clusters with sequence ﬁngerprints that have
been characterized. For A20 CDRs L1–L3 and H1–H2, there was a
unique sequence match to a database cluster, and for H3, four
were possible, two of which could be eliminated later as segments
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density. Median structures coming from the best database cluster
for each CDR were spliced together into a single A20 model after
superimposing their constant regions. The process was repeated
for the alternate H3 conformation. The sequences were then
changed to that of A20, and, where necessary, new side chain
rotamers were selected to resolve clashes or bring side chains into
density. No additional optimization of these database-derived
models was performed. They were used to assess uncertainties in
the homology model and in the model-derived footprint.
Docking and reﬁnement of the homology model
The FAb A20 homology model was ﬁt approximately into a
difference map calculated by subtracting a native cryo-EM recon-
struction from that of the complex (Fig. S3). Initial rigid-group
conjugate gradient reﬁnement was performed with the Flex-EM
option of Modeller-9 (Topf et al., 2008). This revealed two
locations where the automatic homology modeling could be
improved, residues 209–210 that overlapped with residues 263–
264 of AAV-2, and Lys69 which extended beyond the difference
map and clashed with AAV2 325. Residues 205–216 were remo-
deled using another high-scoring homolog (model 554) that did
not conﬂict, and an alternate favored rotamer (Dunbrack, 2002)
was selected for Lys69.
The structure was further optimized using a new implementa-
tion of the real-space reﬁnement RSRef (Chapman, 1995),
embedded in CNS (Bru¨nger et al., 1998). From this point, instead
of using a difference map, the Fab’ model was reﬁned in the
presence of AAV-2 into the reconstruction of the complex. Addi-
tional reﬁned parameters included the relative EM magniﬁcation,
and the ‘‘soft’’ resolution limit of a 5th order Butterworth low-
pass ﬁlter (Frank et al., 1996) applied when calculating the
density of the atomic model. The experimental map had been
corrected (sharpened) by application of the inverse envelope
function with EMB-factor (Fernandez et al., 2008). The low-pass
ﬁlter allowed the model density to replicate the resulting smooth,
but non-Gaussian attenuation near the resolution limit. In reﬁne-
ment, the squared difference between observed and calculated
electron density levels was minimized using all map grid points
within 10 A˚ of any model atom, and considering density con-
tributions from atoms up to 25 A˚ away. Icosahedral symmetry
was imposed as a constraint on both Fab’ A20 and the AAV-2
capsid protein. The virus structure was ﬁxed, aligned to the
icosahedral symmetry of the map. The Fab’ was reﬁned ﬁrst as a
single rigid group, optimizing a weighted (20:1) sum of the
density residual and CNS van der Waals repulsion terms. The Fab’
was then split into variable and constant domains for rigid-group
positional and group B-factor reﬁnement.
Modeling of the A20 structure led to a 0.8 A˚ clash at AAV-2
Lys258. This was resolved by choosing a different high frequency
rotamer for Lys258. The closest remaining contact was 2.4 A˚. No
attempt was made at the subtle adjustments needed to resolve
contacts that were suboptimal by only 0.5 A˚, given the resolu-
tion of this study. The need for at most subtle adjustment of side
chains is consistent with the absence of features in the EM density
indicative of signiﬁcant conformational changes.
Density-based footprint
AAV amino acids contacted by Fab A20 were identiﬁed as
those with any atom within 4 A˚ of any homology model atom. An
alternative model-independent identiﬁcation was performed as
follows: Between the density of the Fab’ and AAV-2, a clear
constriction at the periphery of the interface could be used to
demark an outline. The contour level of 2.2 s was used, because itcorresponded to the calculated Fab’ solvent-excluded volume in a
map of the complex segmented using Chimera (Pettersen et al.,
2004). On the 2.2 s contour of the non-segmented map, the
boundary between Fab’ and AAV-2 was outlined in 3D by
connecting saddle points with markers placed interactively using
Coot (Emsley et al., 2010). The outline was projected onto the
surface of the AAV-2 model using Rivem (Xiao and Rossmann,
2006), identifying AAV-2 amino acids whose surfaces were 425%
covered. A solvent-accessible outline was obtained by extending
the markers outwards by the 1.4 A˚ radius of a solvent probe, and
additional potential contact regions were determined using the
corresponding 1.1 s contour level.Acknowledgments
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